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β2-AdrenoceptorsL-type Ca channels (LTCC), which play a key role in cardiac excitation–contraction coupling, are located predomi-
nantly at the transverse (t-) tubules in ventricular myocytes. Caveolae and the protein caveolin-3 (Cav-3) are also
present at the t-tubules and have been implicated in localizing a number of signaling molecules, including protein
kinase A (PKA) andβ2-adrenoceptors. The present study investigatedwhether disruption of Cav-3 binding to its en-
dogenous binding partners inﬂuenced LTCC activity. Ventricular myocytes were isolated frommaleWistar rats and
LTCC current (ICa) recorded using thewhole-cell patch-clamp technique. Incubation ofmyocyteswith amembrane-
permeable peptide representing the scaffolding domain of Cav-3 (C3SD) reduced basal ICa amplitude in intact, but
not detubulated, myocytes, and attenuated the stimulatory effects of the β2-adrenergic agonist zinterol on ICa. The
PKA inhibitor H-89 also reduced basal ICa; however, the inhibitory effects of C3SD and H-89 on basal ICa amplitude
were not summative. Under control conditions, myocytes stained with antibody against phosphorylated LTCC
(pLTCC) displayed a striated pattern, presumably reﬂecting localization at the t-tubules. Both C3SD and H-89 re-
duced pLTCC staining at the z-lines but did not affect staining of total LTCC or Cav-3. These data are consistent
with the idea that the effects of C3SD and H-89 share a common pathway, which involves PKA and is maximally
inhibited by H-89, and suggest that Cav-3 plays an important role in mediating stimulation of ICa at the t-tubules
via PKA-induced phosphorylation under basal conditions, and in response to β2-adrenoceptor stimulation.
© 2014 The Authors. Published by Elsevier Ltd.Open access under CC BY-NC-ND license. 1. Introduction
The L-type Ca current (ICa) plays a key role in excitation–contraction
coupling in cardiac myocytes: Ca inﬂux via ICa triggers release of more
Ca from adjacent sarcoplasmic reticulum (SR) to cause contraction, and
loads the SR with Ca for subsequent release [1,2]. However ICa is not spa-
tially uniform; it ﬂows predominantly across the t-tubule membrane [3].
One reason for this localization appears to be that basal protein kinase A
(PKA) activity stimulates ICa more at the t-tubules than at the surface
membrane [4]: inhibition of PKAmarkedly inhibits basal ICa in intact ven-
tricular myocytes, but has little effect on ICa after the t-tubules are
uncoupled from the surface membrane (detubulation). This is consistent
with previous work showing that many of the proteins constituting the
β-adrenergic pathway are located predominantly at the t-tubules, and
that β-adrenergic stimulation causes a greater increase of ICa in the
t-tubules than at the surface membrane [5], suggesting better couplinglive.orchard@bristol.ac.uk
. Open access under CC BY-NC-ND licenof β-adrenergic signaling pathways to ICa at the t-tubules than at the cell
surface.
Localization of β-adrenergic signaling is well-recognized: although
the response to β1-adrenoceptor stimulation occurs throughout the
cell, β2-stimulation causes local stimulation of ICa [6]. More recently it
has been shown that β1-adrenoceptors are located across the entire
cell surface, whereas β2-adrenoceptors are found predominantly at
the t-tubules [7]. Thus, localization to the t-tubules of ICa stimulation
by basal PKA activity may involve constitutive activity of the same
pathways as β2-adrenergic stimulation.
However the mechanisms underlying this localization are
unclear. Recent work suggests that caveolae play an important role
in spatially restricting the response to β2-adrenergic stimulation
[8,9]. Caveolae are invaginations of the cell membrane, whose inter-
nal surface is lined with the scaffolding protein caveolin, caveolin-3
(Cav-3) being the prevalent form in adult cardiac myocytes [10].
Caveolin binds a variety of signaling molecules, including PKA, via a
scaffolding domain to form signaling complexes and regulate their
activity. A sub-population of L-type Ca channels (LTCC) also co-
localizes with caveolin in ventricular myocytes [11–13]. Thus it
seems possible that co-localization of PKA and LTCC as a result of
Cav-3 binding underlies localized activation of ICa by PKA activity.
We have, therefore, investigated the role of Cav-3 on the phosphor-
ylation and activation of ICa by PKA activity, by studying the effectse. 
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and the response to altering PKA activity.
2. Materials and methods
2.1. Myocyte isolation and detubulation
Myocytes were isolated from the hearts of male Wistar rats
(250–300 g). All procedures were performed in accordance with UK
legislation and approved by the University of Bristol Ethics Committee.
Animals were killed by cervical dislocation or under pentobarbitone
anesthesia, the heart quickly excised, and Langendorff-perfused at
8 ml/min (37 °C), initially with Tyrode's solution (see below) plus
0.75 mMCaCl2 for 4 min, thenwith 0.9 mMEGTA for 4 min, and ﬁnally
with 1 mg/ml collagenase (Worthington Corp) for 10 min. The left
ventricle was then excised and shaken in collagenase-containing solu-
tion at 37 °C for 5–7 min, ﬁltered, and centrifuged. The supernatant
was discarded and the pellet re-suspended in Kraftbrühe solution, that
contained (in mM): 90 Glutamic acid, 30 KCl, 10 HEPES, 1 EGTA, 5 Na
pyruvate, 20 Taurine, 20 Glucose, 5 MgCl2, 5 Succinic acid, 5 Creatine,
2 Na2 ATP, 5 β-OH Butyric acid, pH 7.4 (KOH) and stored for 2–10 h be-
fore use on theday of isolation.Detubulation (DT) ofmyocytes (physical
and functional uncoupling of the t-tubules from the surfacemembrane)
was achieved using formamide-induced osmotic shock, as described
previously [3].
2.2. Solutions
The Tyrode's solution used for cell isolation contained (in mM): 130
NaCl, 5.4 KCl, 0.4 NaH2PO4, 4.2 HEPES, 10Glucose, 1.4MgCl2, 20 Taurine,
10 Creatinine, and pH 7.4 (NaOH). For patch-clamp experiments, cells
were superfused with a solution that contained (in mM): 133 NaCl, 5
KCl, 1 MgSO4, 1 CaCl2, 1 Na2HPO4, 10 Glucose, 10 HEPES, and pH 7.4
(NaOH); 5 CsCl was either added or used to replace KCl, to inhibit K
currents. The pipette solution contained (in mM): 110 CsCl, 20 TEACl,
0.5 MgCl2, 5 Mg-ATP, 5 BAPTA, 10 HEPES, 0.4 GTP-Tris, and pH 7.2
(CsOH); BAPTA buffers bulk cytoplasmic Ca and Ca within the dyad,
and thus inhibits Ca-dependent inactivation of ICa [5,14]. For immuno-
cytochemistry, the PBS solution contained (in mM): 3.8 NaH2PO4, 16.2
Na2HPO4, 150 NaCl, and pH 7.4 (NaOH).
PKAwas inhibited using 20 μM H-89. Selectiveβ2-adrenoceptor stim-
ulation was achieved using the β2-agonist zinterol (1–10 μM) in combi-
nation with the speciﬁc β1-adrenoceptor blocker atenolol (10 μM); cells
were superfused with atenolol for at least 4 min before application of
zinterol. The speciﬁc β2-adrenoceptor blocker ICI 118,551 was used to
verify the speciﬁc agonist effect of zinterol. A membrane-permeable
TAT-tagged peptide (C3SD; [15]) was used to disrupt binding of Cav-3
to its partner proteins as described previously [16,17]; this peptide corre-
sponds to the 20-residue scaffolding domain of Cav-3 linked by 4 glycine
residues to the 11-residue trans-activating transcriptional activator se-
quence from HIV-1; a scrambled version of this peptide (Scram) with
100% amino acid identity but only 60% sequence identity that has been
shown not to displace Cav-3 binding was used as control [17].
Ventricular myocytes were incubated in 1 μM peptide diluted in either
isolation Tyrode's or Kraftbrühe solution for 30–60 mins at 37 °C. Cells
were then washed in control buffer or used immediately for electrophys-
iological recordings. In some experiments, an antibody against Cav-3
(25 μg/ml, SC-16229, Santa Cruz Biotechnology, Inc.) was incorporated
in the pipette solution to disrupt Cav-3 function. All experiments were
performed at room temperature.
2.3. Recording ICa
Myocyteswere placed in a chambermounted on the stage of a Nikon
Diaphot inverted microscope. Membrane currents and cell capacitance
were recorded using the whole-cell patch-clamp technique, using anAxopatch 200B (Axon Instruments) and aDigidata 1322AA/D converter
(Axon Instruments). pClamp 10 software (Axon Instruments) was used
for data acquisition and analysis. Patch pipette resistance was typically
2–4 MΩ when ﬁlled with pipette solution. Pipette capacitance and
series resistance were compensated by N70%. The voltage protocol
used to elicit ICa was: from a holding potential of −80 mV, a 100 ms
step depolarization to−40 mV was applied to inactivate the sodium
current, followed by a step depolarization to voltages ranging between
−50 and +80 mV (10 mV steps) for 500 ms, before repolarization to
−80 mV, at a frequency of 0.2 Hz. To monitor the response to drug ap-
plication a continuous train of step depolarizations to 0 mV (0.2 Hz)
was used.
2.4. Analysis of ICa
The amplitude of ICa was measured as the difference between peak
inward current and current at the endof thedepolarizingpulse, normal-
ized to cell capacitance and expressed as current density (pA/pF).
Rundown of ICa was monitored for 12 min before application of H-89
(Fig. 3), 5 mins before application of ICI-118,551 (data presented in
text) and 2 mins before application of zinterol (Fig. 6). An exponential
functionwas ﬁtted to the decay in the amplitude of ICa and extrapolated
to the end of the drug application to estimate current rundown.
Current–voltage relationships measured in the presence of H-89
were corrected for this rundown (control −5.4 ± 3.2% and C3SD
−14 ± 2.4%). Inactivation of ICa was quantiﬁed by ﬁtting the decay of
the current from its peak to steady state (at the test voltage) to a double
exponential function (pClamp 10) to give “fast” (τfast) and “slow”
(τslow) time constants. ICa (measured at 0 mV) was converted to




where the reversal potential for ICa (Erev) was calculated for each cell
from the current–voltage relationship. Activation curves were ﬁtted
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where gmax represents the maximum L-type Ca2+ conductance, E0.5 is
the membrane potential at which 50% of gmax is activated and k is a
slope factor.
The zinterol-induced increase in ICa amplitude is expressed as a
percentage of the amplitude of ICa in the presence of atenolol just before
application of zinterol.
2.5. Immunocytochemistry
Phosphorylation of LTCC was investigated using a polyclonal anti-
body to thepore forming subunit (α1c) phosphorylated at Ser1928, gen-
erated as described previously ([18], anti-Cav1.2 phosphoserine-1928,
A010-70, Badrilla Ltd.). This antibody provides a read-out of PKA-
dependent phosphorylation of the LTCC α1c-subunit [19]. Myocytes
were stained with this antibody using standard techniques. In brief,
cells in 1 ml Kraftbrühe solution were placed on poly-L-lysine coated
coverslips and left for 45 min. Cells were then ﬁxed with 100 μl 4%
paraformaldehyde for 10 min and permeabilized using 100 μl 0.1% triton
X-100 in PBS for 10 min. Non-speciﬁc binding was blocked using 100 μl
10% normal goat serum in PBS for 20 min. Cells were incubated with
anti-phospho-Ser1928 antibody (1:100 dilution in PBS with 10% normal
goat serum) overnight at 4 °C, and with ﬂuorescent secondary antibody
(FITC conjugate goat anti-rabbit IgG 1:200 dilution in PBS) for a further
40 min. Coverslipswere rinsed in PBS between each stage. The same pro-
tocol was used to label Cav-3 (anti-caveolin-3 antibody, 610420, BD
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phosphorylated; L-type Ca2+ CP α1C (N-17) Antibody, rabbit, SC-16229,
Santa Cruz Biotechnology, Inc.).
2.6. Confocal imaging
An x-y image was recorded from the center of immuno-labeled
cells using a confocal laser scanning microscope (Leica SP5-AOBS,
Leica Microsystems, Wetzlar, Germany) attached to an inverted
epiﬂuorescence microscope (Leica DM I6000) with excitation at
488 nm (using a 100 mWAr laser) and ﬂuorescence intensity collected
between 500 and 572 nm. All settings were kept constant on a given
day.
2.7. Image analysis
Staining intensity was analyzed using ImageJ software (v1.46,
nih). Due to the variation in staining intensity, it is difﬁcult to com-
pare absolute staining intensities between images. However the dis-
tribution of staining was determined, by quantifying the bands of
transverse staining using a fast Fourier transform (FFT) of the
image. The power of the FFT was normalized and the amplitude of
the ﬁrst harmonic taken as a measure of the intensity of staining at
the z-lines. The reciprocal of the spatial frequency provided a mea-
sure of the average inter-band distance.
2.8. Statistics
Data are expressed as mean ± SEM. Statistical analysis was
performed using GraphPad Prism (GraphPad Software Inc.). Paired
and unpaired t-tests and analysis of variance (1 or 2 way ANOVA)Fig. 1. Effect of C3SD-peptide on the basal amplitude of ICa. A: representative family of current reco
scrambled (Scram,middle) andC3SD-peptide (C3SD, right). The inset shows the voltageprotocol. B
treated (open circle, n=9) and C3SD-treated (ﬁlled circle, n=15) myocytes. C: mean data for the
There is a signiﬁcant difference in the ICa amplitude between the three groups (1-way ANOVA, p b
control and Scram-treatedmyocytes and a signiﬁcant difference between the C3SD-treatedmyocy
of ICa activation. Maximal conductance was reduced by C3SD (see text), there was no differen
−4.8 ± 0.2 mV, n = 11; Scram,−4.9 ± 0.1 mV, n = 9; C3SD,−4.9 ± 0.2 mV, n = 15, ns, 1-wwere used as appropriate with the Bonferroni post hoc test where
appropriate. Statistical signiﬁcance was taken as p b 0.05.
3. Results
3.1. Effect of disrupting Cav-3 binding on ICa and Ca channel phosphorylation
To test the hypothesis that protein binding to Cav-3 is necessary for
basal stimulation of ICa by phosphorylation of LTCC, we investigated the
effect of C3SD and its scrambled control (Scram) on ICa and LTCC
phosphorylation: the C3SD peptide is designed to disrupt normal Cav-
3-dependent protein localization and co-localization by competing
with endogenous Cav-3 for binding partners.
Fig. 1A shows representative traces of ICa recorded from an untreated
myocyte (left) and from Scram- (middle) and C3SD-treated (right)
myocytes. Comparison of the middle and left panels shows that Scram-
peptide had no apparent effect on either the magnitude or time-course
of ICa. However, the traces in the right panel show that C3SD markedly
reduced ICa peak amplitude. Fig. 1B showsmean ICa–voltage relationships
in the three conditions. Although incubation of myocytes with either
Scram or C3SD did not signiﬁcantly alter cell capacitance (control,
179 ± 12 pF, n = 11; Scram, 170 ± 22 pF, n = 9; C3SD, 166 ± 11 pF,
n = 15, ns, 1-way ANOVA), incubation with C3SD-peptide signiﬁcantly
reduced ICa density (p b 0.0001, 2 way ANOVA) across the voltage
range−20 to+20 mV. Fig. 1C shows that the amplitude of ICa (recorded
at 0 mV) was not altered by incubation with Scram peptide but was
signiﬁcantly reduced by incubation with C3SD (p b 0.001 vs Scram).
Similarly, Fig. 1D shows that maximal conductance (gmax) was reduced
in C3SD-incubated myocytes as compared to Scram-incubated cells
(p b 0.05, 1-way ANOVA). There was no difference in the voltage-
dependence of activation of g between the three conditions (E0.5: control,rds taken from an untreated (control) ventricular myocyte (left) andmyocytes incubated in
:meanpeak ICa–voltage relationship recorded fromuntreated (open square, n = 11), Scram-
peak ICa amplitude elicited by a voltage-clamp step to 0 mV for the three treatment groups.
0.001), Bonferroni post hoc analysis shows no statistically signiﬁcant difference between the
tes and control- (p b 0.001) and Scram-treatedmyocytes (p b 0.001). D: voltage-dependence
ce in the voltage-dependence of activation of g, E0.5 (see text) or slope factor (k: control,
ay ANOVA) between the three conditions. Solid lines represent ﬁts to Eq. (2).
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−14.9 ± 1.3 mV, n = 15, ns, 1-way ANOVA). The time course of inacti-
vation of ICa was not signiﬁcantly altered by incubationwith either Scram
or C3SD. Under the recording conditions used, Ca-dependent inactivation
is inhibited [20]. Thus, voltage-dependent inactivationwas not altered by
these peptides.
To investigate whether the effect of C3SD on ICa could be due to
direct block of LTCC, we studied its effect on the response of ICa to the
LTCC agonist Bay K 8644. Bay K increased ICa in both control and C3SD-
treated cells, so that in the presence of Bay K, ICa at 0 mV was not signiﬁ-
cantly different in the two groups of cells (control: −8.3 ± 0.5 to
−9.6 ± 0.5, pA/pF, n = 6; C3SD: −6.6 ± 0.4 to −9.9 ± 1.1, n = 6,
pA/pF), thereby demonstrating that C3SD is not acting as an LTCC blocker.
Importantly, since basal ICawas smaller in C3SD-treated cells, the increase
in current caused by Bay Kwas greater in these cells (control, 16 ± 5% vs
C3SD, 47 ± 9%, p b 0.02). This is consistent with C3SD causing dephos-
phorylation of LTCC, thereby decreasing LTCC open probability (Po):
since Bay K increases Po in a phosphorylation-independent manner, ICa
would be expected to be the same in the presence of BayK8644 in control
and in C3SD-treated cells. Thus, the reduction in the amplitude of ICa
following treatment of cells with C3SD is consistent with the idea that
Cav-3 plays a role in activation of ICa under basal conditions.
To investigate further whether activation of ICa by Cav-3 is due to
channel phosphorylation, we used a phospho-speciﬁc antibody against
the pore-forming LTCC α1c-subunit to determinewhether C3SD also al-
tered LTCC phosphorylation, and compared this with labeling of Cav-3
and total LTCC.
Fig. 2A shows confocal images of representative cardiac myocytes
stained with antibodies against Cav-3 (left), total (i.e. phosphorylated
and non-phosphorylated α1c-subunit) LTCC (middle), or phosphorylated
LTCC (pLTCC, right) under control conditions (top row), and following in-
cubation with either Scram (middle row) or C3SD (bottom row). UnderFig. 2. The effect of C3SD on the expression and localization of caveolin, and non-phosphorylat
anti-caveolin (Cav-3, left column), total (phosphorylated + non-phosphorylated) LTCC (tLTCC
untreated (top row), scram- (middle row) or C3SD-treated (lower row) myocytes. Scale bar re
stained cell. Spectrum corresponds to the control tLTCC image (top, middle column). C: Me
(n = control 4, Scram 7, C3SD 10), Total LTCC (tLTCC, n = control 6, Scram 7, C3SD 6)
***, p b 0.001; Bonferroni post hoc analysis, 1-way ANOVA.normal conditions, the majority of staining for all three proteins
occurred in clear transverse striations, presumably at the t-tubules. The
images in the left and middle columns, and the corresponding mean
data in Fig. 2C, show that neither Scram nor C3SD had any discernible
effect on the distribution of staining for Cav-3 or total LTCC. Similarly,
Scram-peptide hadno signiﬁcant effect on the distribution of pLTCC label-
ing (Fig. 2C); however, C3SD caused a signiﬁcant decrease in the intensity
of the transverse striations observed following staining for pLTCC
(p b 0.001 vs Scram, Fig. 2C). Thus it appears unlikely that the effect of
C3SD on ICa is due to changes in the distribution of Cav-3 or LTCC, but
the data are consistent with the notion that the decrease in ICa caused
by C3SD is due to reduced channel phosphorylation at the t-tubules.
3.2. Effect of PKA inhibition on C3SD-dependent changes of ICa and channel
phosphorylation
To investigate the role of PKA in the changes in basal ICa and
phosphorylation described in Section 3.1, we studied the effect of the
PKA inhibitor H-89 on ICa and LTCC phosphorylation in the absence
and presence of C3SD.
The recordings in Fig. 3A show the effect of H-89 (20 μM) on ICa
(elicited by a voltage-clamp step to 0 mV) in an untreated (left) and
C3SD-treated (right) myocyte. H-89 caused a signiﬁcant decrease in
the amplitude of ICa in both cell groups (Fig. 3B; after 8 min: control:
from −7.6 ± 0.5 pA/pF to −3.6 ± 0.5 pA/pF, n = 5, p b 0.001;
C3SD-treated: from −5.4 ± 0.4 pA/pF to −3.7 ± 0.3 pA/pF, n = 5,
p b 0.001). However, the decrease was greater in control than in
C3SD-treated cells (interaction, p b 0.0001, 2-way ANOVA); H-89
decreased ICa by 53 ± 3% in control cells, and by 22 ± 11% in C3SD-
treated cells (p b 0.05). The effects of H-89 and C3SD on the amplitude
of ICa were not however summative, so that the amplitude of ICa in the
presence of H-89 was not signiﬁcantly different in the absence ored and phosphorylated forms of LTCC. A: representative images of myocytes stained with
, middle column) and phosphorylated LTCC (pLTCC, right column) antibodies, taken from
presents 50 μm. B: representative power spectrum of a longitudinal scan of an antibody-
an z-line staining intensity in control and in Scram- and C3SD-treated cells for Cav-3
and phosphorylated LTCC (pLTCC, n = control 22, Scram 15, C3SD 20). **, p b 0.01;
Fig. 3. The effect of C3SD-peptide on the PKA–dependence of basal ICa. A: representative current records of ICa elicited by a step depolarization to 0 mV taken from an untreated (control,
left) and a C3SD-treated (C3SD, right)myocyte in thepresence and absence of H-89 (20 μM, 8 min, denotedby the arrow). Inset inA shows the voltage protocol. B: time course of the effect
of H-89 (20 μM, denoted by the black bar) in reducing the peak amplitude of ICa elicited by a step depolarization to 0 mV in control (open circles, n = 5) and C3SD-treated cells (ﬁlled
circles, n = 5). C:mean ICa–voltage relationship recorded in the absence (open symbols) and presence (closed symbols) of H-89 from control (circles, n = 5) and C3SD-treated (squares,
n = 5) myocytes. D: mean data for the time course of ICa inactivation in the presence (+) and absence (−) of H-89 in control and C3SD-treated myocytes. E: mean data for the effect of
H-89 on peak ICa amplitude elicited by a voltage clamp step to 0 mV with (n = 7) or without (n = 6) Cav3 antibody in the pipette. Statistical signiﬁcance was assessed using Student's
paired (D) or unpaired t-tests (E); * p b 0.05, **p b 0.01.
Fig. 4. The effect of C3SD and PKA inhibition on LTCCα1c-subunit phosphorylation. A: rep-
resentative images of ventricularmyocytes stainedwith anti-pLTCC antibodies taken from
untreated (top row), scram- (middle row) or C3SD-treated (lower row) in the absence
(left column) or presence (right column) of H-89 (20 μM). Scale bar represents 50 μm.
B: mean z-line staining intensity in the absence (Control: n = untreated 22, Scram 15,
C3SD 20) and presence of H-89 (H-89: n = untreated 26, Scram 6, C3SD 9).
***, p b 0.001 (Bonferroni post hoc analysis, 2-way ANOVA).
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H-89 on the mean current–voltage relationship in each group of cells.
These data show that C3SD decreased ICa amplitude (p b 0.001, 2-way
ANOVA) but that in the presence of H-89 ICa was not signiﬁcantly differ-
ent between untreated and C3SD-treated cells (ns, 2-way ANOVA). The
observation that ICa density was not reduced further by H-89 in the
presence of C3SD than in control suggests that the actions of H-89 and
C3SD share a common pathway, which is maximally inhibited by H-89
but not by C3SD.
H-89 signiﬁcantly reduced the slow, but not the fast, component of
ICa inactivation in both control and C3SD-treated myocytes (p b 0.001,
2 way ANOVA) (Fig. 3D).
To investigate an alternativemethod of inhibitingCav-3 function,we
incorporated anti-Cav-3 antibody in the pipette solution and measured
ICa amplitude in the presence and absence of H-89. Fig. 3E shows that
Cav-3 antibody decreased the amplitude of ICa (p b 0.05, 2-way
ANOVA) and decreased the response to H-89, and that in the presence
of H-89 the amplitude of ICa was similar in the presence or absence of
Cav-3 antibody (ns, 2-way ANOVA). These data suggest that, as for
C3SD-peptide, the effects of antibody and H-89 are not summative,
and are consistent with those obtained using C3SD.
Fig. 4A shows confocal images of myocytes labeled with pLTCC-
speciﬁc antibody in untreated (top row), Scram-treated (middle row)
and C3SD-treated (bottom row) cells in the absence (left column) or
presence (right column) of H-89 (20 μM). As described in Section 3.1
(above), under control conditions, the majority of staining occurred in
clear transverse striations, presumably at the t-tubules; this staining
pattern was not signiﬁcantly affected by Scram, but C3SD-peptide
caused a signiﬁcant decrease in the intensity of the transverse striations
(Fig. 4B). Inhibition of PKA with H-89 caused a similar decrease in the
intensity of the transverse striations, whichwas not signiﬁcantly altered
further by either Scramor C3SD (Fig. 4B). These data are consistentwith
52 S. Bryant et al. / Journal of Molecular and Cellular Cardiology 68 (2014) 47–55the observed changes of ICa: C3SD decreased ICa and the t-tubule-
associated staining, and both were decreased further by H-89 to a
level thatwas not signiﬁcantly different fromH-89 alone. This is consis-
tent with the idea that the observed changes of ICa are due to changes in
LTCC phosphorylation.
To investigate whether the effects of C3SD on ICa are functionally
localized to the t-tubules, we studied the response of ICa to C3SD in
detubulatedmyocytes, inwhich the t-tubules are physically and function-
ally uncoupled from the surface membrane, so that only ICa from the cell
surface is recorded. Representative examples of ICa at 0 mV from a control
cell (left), a detubulated cell (middle) and aC3SD-treateddetubulated cell
(right) are shown in Fig. 5A. Fig. 5B shows the mean current density–
voltage relations for control, detubulated and C3SD-treated detubulated
cells. As reported previously, detubulation causes a decrease of ICa density
across the voltage range and reduced whole-cell capacitance (Fig. 5C).
More interestingly, C3SD had no effect on ICa in detubulated cells,
demonstrating that the decrease of ICa caused by C3SD in intact cells
occurs in the t-tubules (ICa at 0 mV: control, −6.8 ± 0.3 pA/pF,
n = 11; DT,−4.7 ± 0.2 pA/pF, n = 5, p b 0.01 vs control; DT + C3SD,
−4.2 ± 0.4 pA/pF, n = 6, p b 0.0001 vs control).
3.3. Effect of PKA stimulation on C3SD-dependent changes of ICa
The results described above suggest that basal phosphorylation of
LTCC at the t-tubules by PKA, and thus basal ICa stimulation, depends
on Cav-3 binding with its partner proteins via the scaffolding domain.
We therefore investigated whether C3SD also alters the response of ICa
to stimulation of β2-adrenoceptors, which are located predominantly
at the t-tubules [7] and cause local stimulation of ICa [6], since they
may involve the samepathways as those underlying basal phosphoryla-
tion (see Introduction).Fig. 5. The effect of C3SD-peptide on basal ICa in detubulated myocytes. A: representative records
treated (DT, middle), and a formamide and C3SD-treated (DT + C3SD, right) myocyte. B: mean
n = 5) and formamide and C3SD-treated (closed square, n = 6) myocytes. C: Cell capacitance w
treated cells (n = 11, as C3SD had no effect on cell capacity, data from formamide-treated cells wThe representative recordings of ICa in Fig. 6 show that the
concentration-dependent increase of ICa caused by the β2-adrenergic
agonist zinterol in control myocytes (Fig. 6A) was inhibited in C3SD-
treated myocytes (Fig. 6B). The mean data in Fig. 6C show that the re-
sponse to 1 μM and to 3 μM zinterol was abolished in C3SD-incubated
cells. The concentration-dependent response to zinterol was also
inhibited by the β2-adrenoceptor antagonist, ICI-118,551 (Fig. 6D). The
reason for the small, statistically non-signiﬁcant, increase of ICa produced
by the highest concentration of zinterol in the presence of C3SD is un-
known, but since this increase in ICa was not signiﬁcantly different from
that observed in the presence of the β2-antagonist, ICI-118,551
(Fig. 6D), the data are consistent with a role for Cav-3 in the localization
of signaling via the β2-adrenoceptor. Thus, these data are similar to
those reported for mouse ventricular myocytes, which showed inhibition
of β2-adrenergic stimulation of ICa following disruption of caveolae using
Cav-3 siRNA [11]. The data therefore suggest that the Cav-3-localized
β2-adrenoceptor pathway increased ICa by approximately 40%, consis-
tentwith previous reports from rat ventricularmyocytes (e.g. [21]). Ap-
plied alone, ICI-118,551 (5 min, 100 nM) did not signiﬁcantly reduce
basal ICa amplitude (from−9.6 ± 1.5 pA/pF, to −10.1 ± 1.6 pA/pF,
n = 6, p = ns). These data suggest that Cav-3 binding plays a role in
coupling β2-adrenoceptors to ICa and are thus consistent with the idea
that basal stimulation of ICa, which is also disrupted by C3SD (above),
may be due to tonic activity of PKA associatedwith theβ2-adrenoceptor
pathway at the t-tubules.
4. Discussion
The present data show that interventions designed to disrupt protein
binding to Cav-3 decrease ICa in basal conditions and in response to
β2-adrenergic stimulation, and that these decreases are associated withof ICa elicited by a step depolarization to 0 mV in an untreated (control, left), a formamide-
ICa–voltage relationships for untreated (circle, n = 11), formamide-treated (open square,
as reduced by ~30% from 283 ± 22 pF in control (n = 11) to 167 ± 11 pF in formamide-
ere pooled; p b 0.05, Student's unpaired t-test).
Fig. 6. The effect of C3SD-peptide on the β2-adrenoceptor-mediated ICa stimulation. A, B: representative ICa records taken from an untreated (control, A) and a C3SD-treated myocyte
(B) showing the effects of β2-adrenoceptor stimulation (zinterol 1, 3 & 10 μM). The inset in A shows the voltage protocol. C: mean peak ICa elicited by voltage-clamp steps to 0 mV
(0.2 Hz) in control (n = 8, open symbols) and C3SD-treated (n = 7, closed symbols) cells. Atenolol (10 μM)was applied at least 4 min before the application of zinterol; at each concen-
tration of zinterol used in control cells, themaximumeffect on ICa was reachedwithin 3 mins. D:mean data for the zinterol-mediated increase in ICa expressed as a percentage of control in
untreated myocytes (open bars), in myocytes treated with the β2-adrenoceptor antagonist, ICI-118,551 (gray bars, 100 nM, n = 6) or treated with C3SD-peptide (ﬁlled bars).
***, p b 0.001 (Bonferroni post hoc analysis, 2-way ANOVA).
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the hypothesis that Cav-3 plays an important role in the stimulation
of ICa by PKA-induced phosphorylation at the t-tubules under basal
conditions, and in response to β2-adrenoceptor stimulation.
4.1. Localization of the response to C3SD
Previous work has shown that stimulation of ICa by PKA occurs
predominantly at the t-tubules in basal conditions and in response to
β-adrenergic stimulation. Similarly, β2-adrenoceptors are localized at
the t-tubules, and stimulation of such receptors is known to cause a
localized increase of ICa. However themechanisms underlying this local-
ization of activity are less clear, although Cav-3 has been implicated.
The present work shows that a peptide that competes with endoge-
nous Cav-3 for proteins that normally bind to its scaffolding domain
[15–17] causes a marked decrease in basal ICa. A scrambled peptide,
with 100% amino acid identity but only 60% sequence identitywaswith-
out effect on basal ICa, demonstrating the speciﬁcity of action of the
C3SD peptide. Moreover, a similar decrease was observed when anti-
Cav-3 antibody was included in the pipette solution. These data are
compatible with the ICa decrease being due to an effect on Cav-3. The
peptide had no effect on the distribution of staining for Cav-3 or
tLTCC. Thus, the observed effects are unlikely to be due to changes in
the distribution of these proteins, nor is the distribution of LTCC appar-
ently determined by its binding to the Cav-3 scaffolding domain (or vice
versa), at least on the time-scale of the current study, inwhichmyocytes
were exposed to C3SD for a relatively short period in order to affect dy-
namic events such as phosphorylation, rather than longer term changes.
However, the decrease of ICa was associated with decreased t-tubular
staining for pLTCC, and C3SD did not decrease ICa in detubulated cells.
Interestingly, the ICa rundown observed in voltage-clamp experiments,which has been suggested to be due to reduced LTCC phosphorylation,
was also increased by C3SD. The simplest explanation of these data is
that C3SD alters Cav-3 binding, thereby disrupting PKA activity and/or
localization, by either direct or indirect interactions, thus disrupting lo-
calized LTCC phosphorylation by basal PKA activity at the t-tubules, de-
creasing t-tubular ICa. Interestingly, inhibition of Cav-3 binding or PKA
activity (Figs. 2 & 4) also appeared to increase pLTCC signal intensity
at the surface membrane. This may reﬂect more uniform staining,
since the surface membrane will be present throughout the depth of
the confocal slice, whereas the t-tubules are smaller, and unlikely to
be present throughout the slice, resulting in a smaller signal from the
t-tubules than from the surface membrane for the same density of
pLTCC staining. More uniform pLTCC density in the presence of C3SD
and H-89 would be consistent with disruption of local phosphorylation
at the t-tubules by these agents, as suggested above. This also empha-
sizes the localization of staining to the t-tubules in the absence of
these agents, when little surface staining was observed.
In some experiments we investigated the effect of C3SD on the
distribution of PKA and adenylyl cyclase 5/6; although staining was ob-
served at the t-tubules and surfacemembrane, C3SD had little apparent
effect on the localization of PKA or adenylyl cyclase 5/6 to the t-tubules
(not shown). However, the scale of disruption required to alter the
functional interaction between PKA and LTCC may be smaller than can
be resolved using immunohistochemistry and confocal microscopy.
Although images of Cav-3 protein staining indicate that Cav-3 may
not be restricted to the z-lines, the functional data from detubulated
cells suggest that both PKA-dependent [4] and Cav-3-dependent
(Fig. 5) modulation of ICa are conﬁned to the t-tubules, and that the
Cav-3 observed at the surface membrane is not involved in such modu-
lation of ICa. This is of interest, given previouswork showing localization
of β2-receptors at the t-tubules [7] and the observation that treatment
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phospholamban [15], consistent with our hypothesis that Cav-3 under-
lies localization of β2-adrenoceptor activity, and indicates that Cav-3
plays a role in controlling PKA-dependent phosphorylation of other
proteins.
In ventricular myocytes, the majority (~90%) of LTCC are located at
the dyad, a sub-population of LTCC co-localizes with caveolin [11–13],
and a caveolin-linked inhibitor can inhibit ICa [22]. However it is not
clear whether C3SD is acting on dyadic and/or extra-dyadic ICa. In sup-
port of the former, it has been suggested that Cav-3 forms a scaffold in
the dyad that complexes with Cav1.2 and is essential for the inotropic
effects of PKA [23], compatible with the current observations. In con-
trast, Cav-3 has been reported to be absent from the dyad, and
caveolin-targeted Cav1.2 inhibition causes only a small (~15%) decrease
of ICa and no change in contractility, which is unexpected if dyadic ICa is
being affected [24]. However, the decrease of ICa observed in the present
study when Cav-3 (or PKA) function is disrupted is greater than would
be expected from the non-junctional fraction of LTCC (~10%); this may
be due to up-regulation of extra-dyadic LTCC or to coupling to dyadic
LTCC: although direct coupling of Cav-3 to PKA and its target proteins
is one model, there are other possibilities; for example, Cav-3 could
tether PKA, or part of the PKA-activating pathway, outside the dyad,
but sufﬁciently close to regulate dyadic LTCCphosphorylation. It is nota-
ble that the ICa decrease due to PKA inhibition is mirrored by a decrease
in the Ca-transient amplitude in intactmyocytes, but that neither ICa nor
the Ca-transient is affected by PKA inhibition in detubulated cells [4].
Thus the change in the Ca-transient appears to be due to a change in
the function of t-tubular proteins, the most likely candidate being ICa,
which is unexpected if extra-dyadic LTCC were the only target for
localized PKA activity.
Conversely, if C3SD predominantly affects extra-dyadic LTCC, this sug-
gests that these channels are responsible for the changes of ICa induced by
inhibiting basal PKA activity and in response to β2-adrenergic stimulation
(see below). This could explainwhy β2-stimulation has little effect on the
systolic Ca-transient, but raises the question what purpose is served by
stimulating extra-dyadic LTCC.
4.2. The role of PKA in the response to C3SD
The role of PKA in the changes of phosphorylation causedbyC3SDwas
investigated using the PKA inhibitor H-89 and β2-adrenoceptor stimula-
tion. H-89 had a qualitatively similar, but quantitatively larger, inhibitory
effect on ICa amplitude as C3SD. Importantly, the inhibitory effects of the
two interventions were not summative, so that ICa in the presence of
C3SD and H-89 was the same as in the presence of H-89 alone. This sug-
gests that their inhibitory effects on ICa may share a common pathway.
The effect of H-89 on the distribution of LTCC phosphorylation at
Ser1928, a PKA-speciﬁc site [19], was also the same as for C3SD, causing
a marked decrease in transverse staining. Taken together, these data
suggest that H-89 and C3SD decrease LTCC phosphorylation via PKA,
and hence reduce ICa, although this is likely to be by different mecha-
nisms; H-89 has a direct inhibitory effect on PKA, whereas C3SD is
more likely to uncouple PKA or component(s) of the PKA pathway from
LTCC.Nevertheless the lack of summation is consistentwith bothworking
via PKA. The smaller effect of C3SD may be because PKA remains active
and at least some remains in the vicinity of the LTCC, although an effect
of H-89 on other protein kinases cannot be entirely ruled out [25].
The observation that both agents decrease phosphorylation at the
t-tubules is interesting because β2-adrenoceptors have recently been
reported to be localized predominantly at the t-tubules. This localization
could underlie localization of ICa stimulation by basal and stimulated
PKA activity at the t-tubules: both basal and β2-adrenoceptor-stimulat-
ed ICa were inhibited by C3SD, consistent with the idea that the two
responses share a common pathway.
In support of this idea, t-tubules are extensively labeled by antibody to
Cav-3 (this study and [26]), consistentwith electronmicroscopy showingcaveolae in t-tubules, and recent work suggests that caveolae play an
important role in spatially restricting the response to β2-adrenergic stim-
ulation: disruption of caveolae converts the normal localized response to
β2-adrenoceptor stimulation to one that occurs throughout the cell [8].
The association of cAMP-related signaling proteins with LTCC and Cav-3,
via the A-kinase anchoring protein AKAP79/150, and the presence of
phosphodiesterases, have been suggested to underlie localization of
cAMP-signaling, and it has recently been suggested that caveolae not
only limit cAMP production but also maintain SR phosphatase activity,
so that their disruption increases the cAMP signal and allows SR protein
phosphorylation [15]. These data are compatible with present work
showing that Cav-3 appears tomodulate PKA-induced LTCCphosphoryla-
tion, and hence ICa, at the t-tubules. Since the initial submission of this
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